Anemia and Inflammation

Federal Institute of Technology (ETH) Zurich

Status: Completed

Conditions: Iron Deficiency Anemia; Inflammation

Treatments: Biological: Dultavax and Vaxigrip

Study type: Observational

Funder types: Other

Identifiers

NCT03618914

SMILE Study

Details and patient eligibility

About

During inflammation hepcidin concentrations are increased, leading to a decrease in iron absorption. In iron deficiency anemia hepcidin is suppressed due to the activation of erythropoiesis. Whether inflammation or anemia has the stronger effect on hepcidin is uncertain.

Enrollment: 50 patients

Sex: Female

Ages: 18 to 49 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI <27.5kg/m2
• body weight <70kg
• either non-anemic (Hb>12.5g/dl) or anemic (Hb between 8-12 g/dl and ferritin <15ng/ml)

Exclusion criteria

• pregnant or lactating
• chronic disease
• smoking
• inflammation defined as CRP<5mg/L; AGP<1g/L

Trial design

50 participants in 2 patient groups

Non-anemic women

Treatment:

Biological: Dultavax and Vaxigrip

anemic women

Description:

anemia due to iron deficiency

Treatment:

Biological: Dultavax and Vaxigrip